Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

Overview of attention for article published in British Journal of Haematology, April 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#4 of 11,026)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 86 news outlets
policy: 2 policy sources

twitter: 2 X users
patent: 1 patent

Readers on

mendeley: 71 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 14,846 followers.

RT @DrAEvens: Nice analysis by @UIowaCancer Brian Link et al on 2nd line & subsequent therapy & outcomes for #follicularlymphoma via @NCCNn…

Nice analysis by @UIowaCancer Brian Link et al on 2nd line & subsequent therapy & outcomes for #follicularlymphoma via @NCCNnews; median PFS 0·83, 0·69 and 0·68 years following Rx3, Rx4 and Rx5, respectively; need more/effective therapy (#UnmetNee…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.